DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION				
60 Eighth Street NE	1/5/2016-1/13/2016*				
Atlanta, GA 30309	3011755158				
(404)253-1161 Fax: (404)253-1202					
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED					
Marvin O. McCord , Owner	STREET ADDRESS				
Carlton's Dunwoody Pharmacy Corp	5484 Chamblee Dunwoody Rd				
CATILON'S DULIWOODY THAT MADY COLP	TYPE ESTABLISHMENT INSPECTED				
Dunwoody, GA 30338-4133					
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.					
DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: OBSERVATION 1 There is no written testing program designed to assess the stability characteristics of drug products.					
There is no written testing program designed to use					
Specifically, there is no stability data to support the expiration or beyond use dates assigned to several of your non-sterile drug products. In addition, the below products were assigned expiration dates that surpassed that of the Active Pharmaceutical Ingredients (APIs).					
 a) Biest(80/20)/Progesterone/Testosterone 2.5 MG/100MG/5MG Capsule, Lot #12162015@1, Expiration Date: 12/15/16 was produced with the below APIs. 					
$(\mathbf{D} \in \mathbb{N} \setminus \{\mathbf{A}\})$	(b) (4)				
1. Estradiol(b) (4) 2. Testosterone (1) (4)	Expiration Date: (b) (4)				
2. Testosterone (b) (4)	Expiration Date. $(0)(1)$				
 b) Triest(80/10/10)/Progesterone 1.35MG/110MG Capsule, Lot #12292015@2, Beyond use Date: 12/23/2016 was produced with the below APIs: 					
1. Estrone (b) (4) (b) (4) Expiration Date: (b) (4) 2. Estradiol (b) (4) Lot #(b) (4) Expiration Date: (b) (4)					
c) Budesonide, 1MG Capsule, Lot #09142015@1, Expiration Date: 9/13/2016 was produced with					
the below API. 1. Budesonide (b) (4) Lot $\#(b)$ (4) Expiration Date: (b) (4)					
EMPLOYEE(S) SIGNATURE	DATE ISSUED				
SEE REVERSE OF THIS PAGE Tamara J Henderson, Investig Rachael L Cook, Investigator	Jator 1/13/2016 X Tamara J Henderson Timera J Henderson Timera J Henderson Signed by: Tamara Section of -S				
FORM FDA 483 (09/08) PREVIOUS EDITION DESOLETE INS	PECTIONAL OBSERVATIONS PAGE 1 OF 3 PAGES				

	HEALTH AND HUMAN SERVICES ID DRUG ADMINISTRATION		
DISTRICT ADDRESS AND PHONE NUMBER	DATE(8) OF INSPECTION		
60 Eighth Street NE	1/5/2016-1/13/2016*		
Atlanta, GA 30309	FEI NUMBER		
(404)253-1161 Fax: (404)253-1202	3011755158		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Marvin O. McCord, Owner			
FIRM NAME	STREET ADDRESS		
Carlton's Dunwoody Pharmacy Corp	5484 Chamblee Dunwoody Rd		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Dunwoody, GA 30338-4133	Producer of non-sterile drugs		

OBSERVATION 2

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically, your firm has not conducted finished product testing on any of the non-sterile drug products you have produced to ensure the products have the strength and quality they purport.

OBSERVATION 3

The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.

Specifically, your quality control unit has not established any written procedures relevant to the production of your non-sterile drug products. There are no procedures for testing, complaint handling, recalls, cleaning, and maintenance of your facility and equipment.

OBSERVATION 4

The calibration of instruments is not done at suitable intervals in accordance with an established written program and with provisions for remedial action in the event accuracy and/or precision limits are not met.

Specifically, your firm has failed to calibrate your ^{(b) (4)} calibration weight and the ^{(b) (4)}(b) (4) palances used to weigh active pharmaceutical ingredients and components for your drug products. Additionally, there are no written procedures describing the requirements for the calibration of the balances and calibration weight.

SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Tamara J Henderson, Investigator Rachael L Cook, Investigator Times J Henderson Times J Henderson Times J Henderson		DATE ISSUED
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIONS	PAGE 2 OF 3 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION						
DISTRICT ADDRESS AND PHON	HONE NUMBER		DATE(S) OF INSPECTION 1/5/2016-1/13/2016*			
60 Eighth Str	reet NE	FEINUMBER	10-1/13/2010*			
Atlanta, GA 3	L Fax: (404)253-1202	301175	5158			
NAME AND TITLE OF INDIVIDUA						
Marvin O. McC	Cord , Owner	STREET ADDRESS				
FIRM NAME	nwoody Pharmacy Corp	5484 Chamblee D	olee Dunwoody Rd			
CITY, STATE, ZIP CODE, COUN	TRY	TYPE ESTABLISHMENT INSPECTED				
Dunwoody, GA		Producer of non	-sterile drugs			
OBSERVATION 5 Batch production and control records do not include complete information relating to the production and control of each batch. Specifically, the "Compounding Log Sheet" used for (b) (4) Lot $\#(b)$ (4) Topical Anesthetic Lot $\#090315$, and Hydroquinone4%/Tretinoin0.05% Cream Lot $\#06202015A$ do not include documentation that each step in the drug production procedure is accomplished as evidenced by the lack of a review and approval by the quality control unit.						
*DATES OF II 1/05/2016(Tue) X Rachael L Cook Rachael L Cook Jwestgator Signed by: Rachael L. Cook -5	NSPECTION ,1/06/2016(Wed),1/07/2016(Thu),1 	/11/2016(Mon),1/13	/2016(Wed)			
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Tamara J Henderson, Investi Rachael L Cook, Investigato	gator r	1/13/7016 X Tamara J Henderson Tamara J Henderson Invegetar Signed by: Tamara Henderson -5	DATE ISSUED 1/13/2016		
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE IN	SPECTIONAL OBSERVAT	IONS	PAGE 3 OF 3 PAGES		